Preface; Contents; 1: Epidemiology and Etiology of Ovarian Cancer; 1.1 Introduction; 1.2 General Epidemiology of Ovarian Cancer; 1.3 Current Status and Changes of Ovarian Cancer Incidence Rate; 1.4 Current Status and Changes of Ovarian Cancer Mortality; 1.5 International Comparison of Ovarian Cancer Incidence Rate and Mortality; 1.6 Risk Factors for Ovarian Cancer; References; 2: Hereditary Ovarian Cancer; 2.1 Introduction; 2.2 Hereditary Breast and Ovarian Cancer (HBOC): BRCA-­Related Breast and Ovarian Cancer; 2.2.1 Clinical and Molecular Features of HBOC

2.2.2 Ovarian Cancer Screening for Surveillance2.2.3 Risk-Reducing Salpingo-Oophorectomy (RRSO); 2.2.4 Chemoprevention; 2.3 Genes Other than BRCA1/2 Involved in Hereditary Ovarian Cancer; 2.3.1 Mismatch Repair Genes (Lynch Syndrome); 2.3.2 Homologous Recombination Deficiency (HRD)-Related Genes; 2.4 PARP Inhibitors; References; 3: Morphological and Molecular Pathogenesis of Epithelial Ovarian Tumors; 3.1 Introduction; 3.2 Representative Theories Related to the Morphological Pathogenesis of EOTs; 3.2.1 The Theory of the Secondary Müllerian System

3.2.2 The Theory of Imported Disease3.3 Two-Tiered Classification for Clinical, Morphological, and Molecular Pathogenesis; 3.4 Morphological and Molecular Pathogenesis in Four Representative Malignant EOTs; 3.4.1 Serous Carcinoma; 3.4.1.1 High-Grade Serous Carcinoma; 3.4.1.2 Low-Grade Serous Carcinoma; 3.4.2 Endometrioid Carcinoma; 3.4.3 Clear Cell Carcinoma; 3.4.4 Mucinous Carcinoma; References; 4: Screening and Prevention of Ovarian Cancer; 4.1 Introduction; 4.2 Materials and Methods; 4.2.1 Search Strategy and Selection Criteria; 4.3 Results

4.3.1 The Systematic Literature Review4.3.2 Ovarian Cancer Screening in the General Population; 4.3.2.1 CA125; 4.3.2.2 Transvaginal Sonography; 4.3.2.3 Two-Stage Strategies; 4.3.3 Ovarian Cancer Screening in the High-Risk Population; 4.4 Prevention of Ovarian Cancer; 4.4.1 Risk-Reducing Surgical Options; 4.4.1.1 Risk-Reducing Salpingo-Oophorectomy (RRSO); 4.4.1.2 Risk-Reducing Oophorectomy (RRO); 4.4.1.3 Risk-Reducing Salpingectomy (RRS); 4.4.1.4 Tubal Ligation; 4.4.2 Risk-Reducing Pharmacologic Options; 4.5 Prevention of Breast Cancer; 4.5.1 Risk-Reducing Surgical Options

4.5.2 Risk-Reducing Pharmacologic Options4.6 Ovarian Cancer Screening in the Japanese Population; 4.7 Discussion; References; 5: Pathology of Epithelial Ovarian Tumors; 5.1 Introduction; 5.2 Classification and Nomenclature of Epithelial Ovarian Tumors; 5.3 Origin of Ovarian Epithelial Tumors; 5.4 Serous Tumors; 5.4.1 Benign Serous Tumors; 5.4.2 Serous Borderline Tumor/Atypical Proliferative Serous Tumor; 5.4.2.1 Usual Serous Borderline Tumor/Atypical Proliferative Serous Tumor; 5.4.2.2 Micropapillary Variant Serous Borderline Tumor (Noninvasive Low-Grade Serous Carcinoma)

This volume presents the latest advances and the current status of our understanding regarding ovarian cancer, addressing both the basic and clinical aspects of the disease. In terms of basic medicine, the WHO Classification of Tumors of Female Reproductive Organs was revised in 2014, and that version addresses several new concepts and histopathological classifications not previously included. One of the most revolutionary breakthroughs concerns the genesis of epithelial ovarian tumors, shifting the focus from the ovarian surface epithelium to serous tubal intraepithelial carcinomas. Clinically, the mortality rate of epithelial ovarian cancer has gradually increased over the past few decades, making it essential to pursue multidisciplinary treatment and apply novel techniques such as neoadjuvant chemotherapy in daily clinical practice. The primary clinical task is the effective treatment of recurrent ovarian cancer with early palliative medicine. Fertility-sparing surgery may also be pursued depending on histologic subtypes, stage, extent of disease, and preexisting ovarian reserve with the concept of oncofertility. On the basis of the considerations described above, each expert author elucidates the science of ovarian cancer in detail, thus providing a collection that will benefit young medical oncologists and seasoned gynecologists and obstetricians alike.